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Management of Hypertension in Women of Childbearing Age  
Abstract 
This literature review was based on a successful completion of an Objective Structured 
Clinical Examination (OSCE) and oral defense. A case report was analyzed, and the topic, 
“Management of hypertension in women of childbearing age,” was developed. Research was 
done using databases such as CINAHL, PubMed, and Cochrane.  Keywords used included 
“Management,” “hypertension,” and “childbearing women,” filtered by publication date range 
from 2001 to 2016.   Recommendations from the 2014 Eighth Joint National Committee (JNC8), 
the Unites States Preventive Service Task Force (USPSTF), the American Society of 
Hypertension (ASH), and the international Society of Hypertension (ISH) were reviewed. The 
literature used in these articles and guidelines was consistent with respect to the definition of 
hypertension, treatment, and management both for women of childbearing age and pregnant 
women.  ASH and ISH, however, have issued clinical practice guidelines for the management of 
hypertension that differ in some areas from JNC8 panel’s recent clinical guidelines. In a 
Cochrane review of clinical guidelines related to pharmacological management of hypertension 
in women of childbearing age, the following observations were made: 
 Women may require different hypertensive regimes in association to differences in the 
progression of hypertension. 
 Pre-menopausal women often require different medication regimes due to the potential 
for pregnancy, being pregnant, and breastfeeding. 
 The use of contraceptive and hormones replacement therapy also complicates the disease 
and its management. Some of the hypertensive medications do have adverse effects, 
many are particularly problematic to women (Dubrey, 2013).  
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Background and Rationale 
      Hypertension is defined as consistent blood pressure (BP) greater or equal to 140/90mm 
Hg, regardless of gender differences or race; this standard is used in classification of 
hypertension considering the epidemiological relationship between increased blood pressure and 
cardiovascular disease (Magee, 2001). Blood pressures have various stages for men, women, and 
different races. Stage 1 hypertension is BP > 140/90mm Hg, stage 2 is a BP >160/100mm Hg, 
and severe BP is defined as systolic pressure > 180mm Hg and/or diastolic BP >110mm Hg. 
(Dubrey, 2013). These stages correlate with the treatment regimen ultimately prescribed. For 
example, in pre-hypertensive stage, lifestyle modification is strongly recommended, whereas 
pharmacologic treatment is required for patients diagnosed with stage 2 or severe hypertension 
(Nguyen, Dominguez, Nguyen, and Gullapalli, 2010). 
Despite the increased proportion of women worldwide (approximately 25% in 1975–
1980 to about 40% in 2000–2005), few studies or clinical trials focus attention on women 
subjects (Ljungman, Mortensen, Kahan, and Manhem, 2009).  Women of childbearing age 
warrant a special attention from clinicians due to possible reproductive goals and potential risks 
of exposing unborn fetus to harmful side effects of pharmacologic treatments.  In general, a 
diagnosis of hypertension increases an individual’s risk of cardiovascular disease, such as stroke 
and renal failure. For women of childbearing age, hormonal changes, hormone-based 
contraception, replacement therapy, and pregnancy contribute to the different impact of 
hypertension on women that calls for differential modification and management strategies. It is 
important, for example, for a clinician to be aware of a woman’s method of birth control when 
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having patients of this age group and gender because some contraceptives are known to elevate 
BP levels (Magee, et. al, 2010). 
 Risk of an unplanned pregnancy is another reason to monitor women of childbearing age 
carefully.  According to McGee (2001), 50% of pregnancies are unplanned, and inadvertent early 
exposure to antihypertensive agents, capable of acting as teratogens, may lead to birth defects.  
ACE inhibitors and angiotensin receptor antagonists are examples of teratogenic agents that 
women who are pregnant or plan to become pregnant, should avoid. The dilemma for patients, 
doctors, and clinicians is that these medications are useful for maintaining health for some 
women of childbearing age with essential hypertension. In such circumstances, clinicians should 
strongly encourage women to seek alternative methods of BP management before and during 
pregnancy and while breastfeeding (formula feeding may have to be prescribed if a mother must 
resume therapy soon after delivery). Treatment goals of hypertension in women of childbearing 
age should necessarily aim to decrease cardiovascular risk as well as prevent pre-eclampsia and 
eclampsia and improve maternal and fetal outcomes for pregnant women; this is effective with 
absolute control of blood pressure levels, as well as a reduction of the risk of hypertension-
related damage to target organs (Brown & Garovic, 2014). 
In addition to presenting a case report of the clinical assessment of a woman with 
hypertension, this report will attempt to use the literature to answer the following questions:  
1. What is the prevalence of hypertension among women of childbearing age? 
2. What are the risk factors and co-morbidities at stake? 
3. What are the practice guidelines for managing the hypertension of women of childbearing 
age?  
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4. What does the clinical or pharmacological literature suggest about appropriate ways of 
managing hypertension of women of childbearing age?   
The paper concludes by summarizing the clinical significance of studying women of 
childbearing age, defined as women ranging from age 15 to 44, who may or may not become 
pregnant, and the major learning points for the clinician presented with the responsibility of 
managing hypertension for women of this age group. 
Prevalence and Incidence 
In a review article, Moodley warned that the “incidence of hypertension in young women 
is likely to increase in the near future because of the rising rates of the metabolic syndrome, 
obesity and dyslipidaemia worldwide. Consequently, more women will be on antihypertensive 
agents, which have the potential for teratogenicity” (Moodley, 2011, p.330).  A US study reports 
that the prevalence of hypertension among women of childbearing age, 20-44years, is 7.7% 
(Dubrey, 2013). One to six percent of women aged 18 to 44 years have hypertension, though 
there is variation of hypertension among different ethnic groups. Women of African-American 
descent have a higher prevalence of high blood pressure than any other race, with incidence 
starting at younger age and being more severe (Dubrey, 2013).  Furthermore, according to 
Dubrey, hypertension is one of the most complicated medical conditions that affect about 10%-
15% of pregnant women. Complications of hypertension in pregnant women, which includes 
pre-eclampsia, eclampsia, cardiovascular problems, and maternal and fetal complications occur 
in about 3%-5% of pregnancies (Dubrey, 2013).  Young women or premenopausal women tend 
to have low blood pressure, and as a result, are at low risk of cardiovascular disease and are less 
in need of being placed on anti-hypertensive medications (Dubrey, 2013).  
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Risks Factors 
Many risk factors predispose women of childbearing age to high blood pressure; these 
include obesity, family history, and unhealthy lifestyle.  The most significant contribution to 
hypertension in women is obesity, and there is an increased relationship of BP and BMI >25 
(Dubrey, 2013). Other contributing factors are lack of exercise, (with only 24% of women 
exercising for the recommended 30 minutes a day), and the impact of increased salt intake on 




This segment describes a clinical assessment of a woman in her late forties, who has been 
diagnosed with hypertension and treated with ACE inhibitor to control her blood pressure. 
During the “clinical visit” in question, the patient reported excessive and nagging cough which 
began after she started  a prescribed medication, lisinopril, for her BP. She routinely did home-
bound monitoring of blood pressure and noted it was consistently high. During the encounter, 
she was diagnosed with ACE inhibitor-induced cough, and treatment modalities were initiated. 
The details of her assessment appointment cover, the history of her illness, past medical history, 
family and social history, system review, the results of her physical examination and the 
recommended care plan following diagnosis. 
Patient Description and History of Present Illness (HPI) 
 On February 5, 2016, this student-clinician evaluated a 48-year old Black American 
female “patient” whose chief complaint was a “nagging cough” that has lasted for two weeks.  
During routine questioning, this student-clinician discovered the patient has a family history of 
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hypertension and a recently diagnosed high blood pressure—she reported being diagnosed with 
high blood pressure about 6 weeks ago. The patient described how she was randomly checking 
her blood pressure at home with her father in-law’s BP-monitoring machine when she noticed 
that her BP was elevated. She subsequently went to the clinic to have it checked, and it was 
indeed elevated. After initial lifestyle modification regimen failed to yield desired BP levels, she 
was prescribed Lisinopril, 20 mg daily. Patient came to the “clinic” for additional assessment of 
February 5
th
 because she had been having nagging dry coughs, day and night, since she started 
taking the medication: “I have this nagging cough for 2 weeks now,” she stated. She also 
reported that nothing made it better or worse; coughing was continuous, woke her up from sleep, 
and interfered with her daily activities.  Patient stated that the pharmacist told her the cough was 
a possible side effect of the BP medication, and patient wondered if that could be the cause of 
her cough. Further review of her of medical chart revealed the following details:  




2. Tubal Ligation 
Medications: 
1. Lisinopril 20 mg daily 
2. Tylenol as needed 
3. Women’s MTV daily 
Allergies: NKDA 
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Family History: 
1. Father: Type 2 diabetes, high blood pressure, high cholesterol and heart stent. 
2. Mother: Osteoporosis and high blood pressure 
3. Brother: High cholesterol and high blood pressure  
4. Sister: Breast Cancer 
Socio-economic History: Patient does not exercise regularly. She does desk work. She denies 
smoking or using illicit drugs, although she drinks 1 to 2 glasses of wine most evening.  
Screening:  
1. Pap Smear: 3 years ago  
2. Mammogram every year 
Review of System: 
1. General: Denies fever, malaise or unexplained weight changes. 
2. HEENT: Denies headaches or recent head injury 
3. Cardiovascular: Denies chest pain or heart palpations. No history of heart murmurs. 
4. Respiratory: Denies dyspnea, no chest tightness. 
5. Gastrointestinal: Denies nausea, vomiting, and constipation 
6. Neurologic: Denies headaches, syncope or seizures.  
 
Physical Examination Results, Assessment, and Plan of Care 
Physical Examination: 
A complete examination on the day of her appointment with this student clinician 
revealed the following physical conditions: 
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1. General: Alert and oriented x4. Good historian and answer questions appropriately. 
Good hygiene. 
2. Vitals: BP 142/78: P 72: R14: BMI 27 kg/m2 
3. HEENT: Atraumatic, no glasses, PEARL, EOMs intact Ears symmetrical, no tenderness 
or discharge. 
4. Respirations: Lungs sound clear all fields; no crackles or wheezing  
5. Cardiovascular: Regular heart rate with no murmurs. No peripheral edema. 
6. Neurological: Cranial nerve I-XII grossly intact. 
7. Differential Diagnosis: 
a. Upper respiratory infection 
b. Asthma  
c. ACE induced cough.  
8. Labs/Imaging: 
                        Basic Metabolic Panel (BNP) and Complete blood Count (CBC). WNL 
a. BMP: BUN 28 mg/dL, Na 140 mmol/L, K 3.9 mmol/L, Cl 105 mmol/L, CO2 27 
mmol/L, Glucose (non fasting) 120 mg/dL, Creatine 0.9 mg/dL, calcium 8.8 
mg/dL, MDRD eGFR >60 
b. WBC: (K/MCL)  9.0, RBC (M/MCL) 48, Platelet (K/MCL) 163, Hgb (G/DL) 
12.5, Hct (%) 45, MCV (FL) 88, MCHC (G/DL) 34, MCH (PG) 32. 
Assessment:  
1. ACE inhibitor-induced cough;  
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2. Patient’s symptoms result most likely from the side effects from Lisinopril ACE 
inhibitor. Patient’s symptoms started after she begins taking the medications. Her 
blood pressure is somewhat reduced but likely not tolerating the medication. 
Care Plan: 
1. Discontinue Lisinopril 20 mg PO daily. 
2. Start Losartan 50 mg PO daily for hypertension 
3. Encourage patient to:  
a. exercise daily to mitigate against the effects of a sedentary desk job  
b. Monitor blood pressure at home 
c. Report any side effect of medication  
d. Call if symptoms persist 
e. Report back to the clinic within 2 weeks. 
 
Literature review 
   The main emphasis of this literature review is to examine evidenced-based 
recommendations for the management of hypertension in women of childbearing age. In addition 
to early or routine screening, the two main interventions for the control and management of high 
blood pressure in women of childbearing age are lifestyle modification and drug therapy.  
Early Screening  
Early or routine is designed to identify pre-hypertensive problems before they become 
magnified.  Hypertension disorder in pregnancy is a major cause of maternal, fetus, and neonatal 
morbidity and mortality. Women should be assessed and evaluated for their blood pressure status 
before conception, and for hypertensive women planning to become pregnant, it may be advised 
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before conception to change their antihypertensive medications which are known to be safe 
during pregnancy (Dubrey, 2013).  
The USPSTF (2011) recommends screening for blood pressure in adults age 18 and over. 
Strategies include ambulatory blood pressure monitoring and homebound blood pressure 
monitoring. Ambulatory monitoring measures blood pressure every 20-30 minutes over the 
course of 24 to 48 hours of normal activities. The 2014 Eighth Joint National Committee (JNC8) 
has specific recommendations regarding effective methods of measuring blood pressure.  These 
include appropriate cuff size, patient position, and multiple readings (JNC8, 2014). White coat 
hypertension, which may be noted in some women at earlier stages of pregnancy, can be 
mistaken for gestational hypertension (Brown & Garovic, 2014). Proper recording of blood 
pressure helps to identify women with white coat hypertension. 
Lifestyle Modification Therapy  
Once a diagnosis has been made, the primary goals for blood pressure intervention are to 
help patients maintain blood pressure control with lifestyle modifications (fostering self-
management skills) and through drug therapy (Hannah & Hyeoun, 2016). According to the 2014 
Evidence-Based Guidelines adopted in 2014 by the Joint National committee (JNC8) for the 
management of high blood pressure in adults 18 years and older, lifestyle modification should be 
recommended as the first line of management of high blood pressure. The second step is setting a 
blood pressure target based on patient’s age, co-morbidities such as diabetes mellitus, and 
chronic renal status, and obtaining this therapeutic target through drugs management.  
Lifestyle modification is worth considering because it helps reduce BP, improve the 
effectiveness of anti-hypertensive medications or eliminate the need for medication altogether. 
(Magee, 2001).  Lifestyle modifications that must be adhered to are smoking cessation, 
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decreased salt intake, exercise, bodyweight reduction, and moderation in alcohol consumption 
(Magee, 2001).  
Since obesity triples the risk of developing hypertension in women, patients who are 
obese should be asked about their diet and exercise pattern and offered education and written 
guidance.  Increase consumption of fruit and vegetables and reduction in fat content can improve 
the patient’s diet and impact risk factors for hypertension (charlotte, 2013). 
Reduction in sodium consumption can decrease the risk of hypertension. Patients are 
encouraged to reduce their sodium intake or follow a cardiac diet. Smoking cessation is of 
utmost importance. Tobacco use can cause vascular disease and contribute to hypertension. 
Clinicians should advise cessation and offer treatment (Easton, 2006). These recommendations 
have proven to be therapeutic in reducing high blood pressure in young women. 
Lifestyle modifications are also used to help address cardiovascular risk factors. 
According to Magee (2001), smoking cessation, moderate alcohol use, and reduction in BMI 
would help lower blood pressure, eliminate or decrease use of anti-hypertensive medications, and 
enhance effectiveness of anti-hypertensive medications (Magee, 2001).  
Pharmacology Therapy 
Various factors are considered before initiating medications therapy for patient who 
needs anti-hypertensive treatments. Women of childbearing age require modification to 
hypertensive drugs therapy at different stages of their lives because of concomitant therapies, 
including contraceptive, hormonal therapies, and other women-related issues (Dubrey, 2013). 
Clinicians should consider the cost of medications, patient preference, history of adverse 
effects, potential interactions with other medication the patient is taking, pregnancy, and other 
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co-morbidities (Magee, 2001). The choice of therapy should be based upon efficacy, safety, cost, 
convenience, and other patient-related factors such as dosing regimen and delivery. 
The 2014 National Joint Committee (JNC8) recommended diuretics, calcium channel 
blockers (CCBs), angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor 
blocker (ARB) as first line of treatment, especially when there are associations with other 
diseases. Some patients may need two or more anti-hypertension medication for lowering blood 
pressure. However, women of childbearing age, or those planning to become pregnant, are 
advised to avoid ACE inhibitors and angiotensin II receptor blockers (ARB) due to potential fetal 
effects. Beta- blockers should be used in premenopausal women as alternative to CCBs, ACE 
inhibitors, or ARBs (Nguyen et al, 2010). According to the study by Simon Dubrey, the 
percentage of women who developed ACE-induced cough is higher in women than men, with 
some other studies indicating that women are twice as affected as men (Dubrey, 2013).    
Diuretics  
      Diuretics are widely used among premenopausal or non-pregnant women mostly because 
of their low cost and availability, and it is considered effective with major cardiovascular 
problems. Diuretics can be divided into three groups: Thaizide, loop, and potassium-sparing 
diuretics. Diuretics reduce blood pressure by promoting natriuresis and reducing intravascular 
volume. Thaizides act to inhibit the absorption of sodium and chloride in the distal convoluted 
tubule. Thaizides are particularly beneficial for stroke, heart failure, and coronary artery disease 
(CAD) patients. Diuretics are shown to be effective for black women and in combination with 
beta-blocker or ACE inhibitors. The side effect of diuretics is hypokalamia, and impaired 
glucose tolerance can be reduced with medication dosage management, such as using low doses 
not more than 25 mg of hydrochlrothiazide (Magee, 2001). According to Magee (2001), early 
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studies reported concerns that thaizide diuretics may cause neonatal thrombocytopenia, but no 
evidence of increase of this problem of neonatal exposed to thaizides diuretics were found. 
Despite early concern of neonatal effect, Nguyen et al., (2010) found no negative effect on fetal 
growth as early believed.      
Beta-Blockers 
Like diuretics, beta-blocker are inexpensive, readily available and frequently used for the 
treatment of hypertension in nonpregnant women. Magee’s (2001) study has shown that these 
class of medication are effective in decreasing cardiovascular risk problem, renal sympathetic 
output, rennin production and sodium excretion, and cardiac output as a result of reducing heart 
rate. Beta- blockers are not effective for the management of hypertension in black race because 
of low rennin hypertension (Magee, 2001). Atenolol is another popular beta-blocker that is 
widely used because it is effective with cardiovascular-risk patient. Some of the side effects of 
beta-blockers are bronchospasm and lethargy; some patient may experience poor sleep (Magee, 
2001). 
ACE inhibitors 
ACE inhibitors are effective in lowering blood pressure by inhibiting the conversion of 
the inactive angiotensin I to the active angiotensin II, and as a result decreasing the production of 
angiotensin II and aldosterone, to produce vasodilation and increase bradykinins and 
prostaglandins (Nguyen et al., 2010).  ACE inhibitors are widely tolerated medications and are 
now popularly used for women of childbearing age. ACE inhibitors are also a preferred choice to 
ARB due to cost effectiveness; ARB should be used in place of ACE only if there are intolerance 
with ACE inhibitors, such as cough and angioedema (Nguyen et al., 2010). ACE inhibitors have 
some adverse effects, including dry cough—it may cause renal failure in some patient with 
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kidney disease (Magee, 2001). It is not recommended that ACE inhibitors be used during second 
and third trimester of pregnancy due to their association with fetopathy. Studies have shown use 
of this medication may cause fetal distress, fetal death, oligohydramnios. They may also cause 
such neonatal issues as renal failure, pulmonary hypoplasia, joint contractures, and intrauterine 
growth restriction. Long-term use of ACE inhibitors increases the risk of fetal physiology and 
ACE inhibitors and angiotensin receptor antagonist in association should be stopped during 
pregnancy (Magee, 2001).       
Calcium Channel blockers 
Calcium channel blockers (CCBs) are anti-hypertensive medications used to lower blood 
pressure; they are widely used for non-pregnant women, though nifedipine has been prescribed 
in later pregnancy. Calcium channel blockers act by preventing calcium from entry into vascular 
smooth muscles, leading to vasodilation and reduction in vascular contractility. The literature has 
shown calcium channel blockers are first-line of drugs and are effective when used in 
combination with other anti-hypertensive medications. It is as well-tolerated, especially when 
combined with ACE inhibitors, but less effective when combined with diuretics because both 
have natriuretic effects (Nguyen et al., 2010). JNC7 recommends CCB as first line drug for use 
for high-risk cardiovascular patients and diabetes (JNC8, 2014).      
Angiotensin Receptor Blockers 
Angiotensin receptor blockers (ARBs) act by blocking angiotensin II from binding to its 
receptors, as a result inhibiting it from causing vasoconstriction and fluid retention. ARBs are 
more costly than ACE inhibitors but have similar blood pressure effects. Cost-effectiveness 
analysis shows ARB proving to be more expensive to initiate than ACE. ARB can be initiated if 
there is intolerance with ACE inhibitors (Nguyen et al., 2010).   
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Combination Therapy 
    Patients with uncontrolled blood pressure may benefit from combination therapy; this 
should be initiated when the target blood pressure goal is not achieved with mono therapy and 
when BP is above 20/10 mm Hg. Each anti-hypertensive medication has a different mechanism 
of action; using two or more anti-hypertension medications allows for applying complementary 
mechanisms to lowering blood pressure effectively. Some of the benefits for fixed combination 
therapy include faster response, fewer side effects from medications, and better compliance 
(Nguyen et al., 2010). ACE inhibitors or ARBs combined with diuretics have shown to be 
effective in lowering blood pressure and with fewer side effects in all genders.  Also, the 
combination therapy of CCB with ACE inhibitors is effective, but the combination of ACE 
inhibitors and ARB is not preferred because it results in increased risk of side effects. Nguyen et 
al., (2010) further cite studies reporting that the combination of ACE and ARB potentiates risks 
of hypotension syncope, renal problem, and hyperkalamia (Nguyen et al., 2010). 
Resistant Hypertension 
  Resistant hypertension is the failure of three anti-hypertensive medications to control a 
patient’s blood pressure effectively, including a tolerated dose of diuretic. The most effective 
way to manage anti-hypertensive treatment failure is to reevaluate conditions that may be 
responsible for lack of blood pressure control and to develop an aggressive anti-hypertensive 
treatments plan with well-tolerated doses. Some factors that may contribute to treatments failure 
are BP measurement technique; white coat effect; poor compliance and inappropriate dosing; use 
of non-prescribed medications, such decongestants; excessive use of alcohol; increased dietary 
sodium intake; obesity; and diabetes mellitus (Nguyen et al., 2010). It is recommended that a 
fourth anti-hypertensive agent be added to the treatments regimen if blood pressure is still not 
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achieved. An evidence-based study has shown that adding spironolactone may be effective in 
lowering BP. Patient who are obese or have sleep apnea may benefit from spironolactone and 
should be considered using because of association with aldosterone excess (Nguyen et al., 2010). 
 
Clinical Significance of Literature Review and Major Learning Points 
Several researchers, (Dubrey, 2013, Yoder, Thornburg, and Bisognano, 2009, and Magee 
et. al., 2001), have made clear the clinical significance for studying women of childbearing age.  
The literature shows consensus that this group poses a unique challenge for clinicians with 
respect to monitoring and managing hypertension.  As Yoder et. al put it:  “Women of 
childbearing age with hypertension represent an interesting and challenging population. As a 
general rule, women tend to have lower blood pressure than men. There is an age delay in the 
development of hypertension such that most women do not require hypertensive therapy during 
their childbearing years. However, the increasing prevalence of obesity and metabolic syndrome 
can herald increased numbers of younger women presenting with hypertension.”  
Clinical Significance 
A listing provided by Yoder et. al. (2009, p. 891) further illustrates the consensus found 
in the literature about clinical significance (the take-away message for clinicians):  
 Hypertension goals for women of childbearing age are the same as for other groups.  
 
 Physicians should consider reproductive goals when selecting medications.  
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 Hypertension during pregnancy is often a symptom of an underlying syndrome with 
significant maternal and fetal morbidity and mortality.  
 
 Early recognition and prompt treatment of hypertensive disorders during pregnancy are 
necessary to avoid deleterious outcomes.  
 Hypertensive disorders of pregnancy likely portend future cardiovascular disease.  
Major Learning Points 
According to Dubrey, (2013), while the guidelines for the management of hypertension 
are similar in both genders, the clinical management may require considerable modification for 
women of childbearing age. Therefore, careful considerations regarding hypertension treatment 
goal, choice of medication for young women who are or might become pregnant, and women of 
childbearing age using contraceptive or replacement therapy should always be in the clinician’s 
mind. 
 The goal of hypertension treatment in women of childbearing age is to reduce blood 
pressure to 140/90mm. Drug therapy is initiated if lifestyle modification cannot 
adequately bring blood pressure to goal. 
 Lifestyle assessment and potential modification are the first step in hypertension 
management. Education should focus on risk factors associated with hypertension, 
including sedentary lifestyle, overweight, smoking, high alcohol consumption, and 
salt intake. 
 In pregnancy-related hypertension, the risk to mother and fetus must be considered 
against any potential for serious drug induced side effect. Clinician should 
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discontinue ACE inhibitors and ARBs within 2 days of notification of pregnancy and 
start alternatives substitutes.       
 Hypertension disorder is the most common medical complications in pregnancy.  
 Women of childbearing age require modification to hypertensive treatment related to 
their ‘phase’ of life, concomitant therapies; including hormonal therapies (Dubrey, 
2013).          
Conclusion 
This paper posed four clinical research questions about women of childbearing age. The 
literature review has shown that women of childbearing age warrant special attention of the 
clinician due to possible reproductive goals and potential risks of exposing unborn fetus to 
harmful effects of pharmacologic treatment. The review has also identified lifestyle modification 
therapy and pharmacologic guidelines for managing hypertension in women of childbearing age. 
The benefits of lifestyle changes are enormous, regardless of the use of anti-hypertensive 
agents. The main issue with lifestyle changes is consistency; many people do not continue to 
comply with recommended changes over time. This problem must be addressed to sustain most 
treatment benefits (Lindsay, 2013). Effective lifestyle changes may benefit young women by 
preventing or delaying onset of hypertension, preventing the need for medical treatment in those 
with stage 1 hypertension, and contributing to a reduction in blood pressure in patients already 
taking anti-hypertensive medication (Lindsay, 2013). Young women of childbearing age who are 
not pregnant with mild-to-moderate hypertension should be encouraged to initiate lifestyle 
modifications; anti-hypertensive medications may not be necessary because of low 
cardiovascular risk. 
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With respect to pharmacologic treatment options, women of childbearing age with severe 
hypertension should immediately commence anti-hypertension therapy to decrease the likely risk 
of cardiovascular problems.  Appropriate medication dosing is required to avoid potential 
ischemia of maternal organs or the placenta and fetus should the women become pregnant 
(Magee, 2001). If anti-hypertensive medication is required, ACE inhibitors and ARBs are 
contraindicated during pregnancy. All anti-hypertensive medications have been proven not to be 
teratogenic if inadvertent exposure occurs in early pregnancy. Teratogenicity may be indicated 
for mid and late trimesters. There is not enough evidence to support treating non-severe 
hypertension during pregnancy, though various choices of anti-hypertensive medications for 
managing severe hypertension during pregnancy, Methyldopa and Beta-blockers, other than 
Atenolol, are mostly used (Magee, et al 2011). Therapy initiated for severe hypertension 
(160/110 mm Hg) during pregnancy should be done to avoid maternal stroke, possible eclampsia 
or direct morbidity and mortality associated with hypertension—intracerebral hemorrhage and 
stroke (Yoder et al. (2009, p. 895). 
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